EC clears acquisition of HRA Pharma
The European Commission has approved under the EU Merger Regulation the acquisition of HRA Pharma by Astorg Asset Management, a private equity investment firm and Goldman Sachs, a global investment banking, securities and investment management firm.
The Commission concluded that the transaction would raise no competition concerns, given that there are no overlaps between the activities of HRA Pharma, a French company that develops and sells pharmaceutical products and devices in women health and endocrinology sectors, on the one hand and the activities of portfolio companies controlled by Astorg and Goldman Sachs, on the other hand.
The transaction, which was announced last year, was examined under the simplified merger review procedure.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
More Features in Pharmaceutical
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze